Trump policies mark a turning point in debate over U.S. drug price controls

Policies and proposals on importation, discounting and subsidies unveiled by the Trump administration this week will not alter the economics of the biopharma industry in the short-term but could nonetheless be an inflection point in the decades-long battle over U.S. drug price controls.

The most obvious impact of the policies would be if they achieve their intended purpose: bolstering the re-election prospects of President Donald Trump and increasing the odds that Republicans retain control over the Senate. ...